Page 246 - 2019_05-HaematologicaMondo-web

1092
haematologica | 2019; 104(5)
N.S. Majhail et al.
Transplant Survivor Study. Blood. 2010;
116(17):3129-3139; quiz 3377.
11. Baker KS, Ness KK, Weisdorf D, et al. Late
effects in survivors of acute leukemia treated with hematopoietic cell transplantation: a report from the Bone Marrow Transplant Survivor Study. Leukemia. 2010; 24(12):2039-2047.
12. Majhail NS, Ness KK, Burns LJ, et al. Late effects in survivors of Hodgkin and non- Hodgkin lymphoma treated with autolo- gous hematopoietic cell transplantation: a report from the bone marrow transplant sur- vivor study. Biol Blood Marrow Transplant. 2007;13(10):1153-1159.
13. Majhail NS, Douglas Rizzo J. Surviving the cure: long term followup of hematopoietic cell transplant recipients. Bone Marrow Transplant. 2013;48(9):1145-1151.
14. Battiwalla M, Hashmi S, Majhail N, Pavletic S, Savani BN, Shelburne N. National Institutes of Health Hematopoietic Cell Transplantation Late Effects Initiative: Developing Recommendations to Improve Survivorship and Long-Term Outcomes. Biol Blood Marrow Transplant. 2017;23(1):6-9.
15. Battiwalla M, Tichelli A, Majhail NS. Long- Term Survivorship after Hematopoietic Cell Transplantation: Roadmap for Research and Care. Biol Blood Marrow Transplant. 2017;23(2):184-192.
16. Majhail NS. Long-term complications after hematopoietic cell transplantation. Hematol Oncol Stem Cell Ther. 2017;10(4):220-227.
17. Syrjala KL, Artherholt SB, Kurland BF, et al. Prospective neurocognitive function over 5 years after allogeneic hematopoietic cell transplantation for cancer survivors com- pared with matched controls at 5 years. J Clin Oncol. 2011;29(17):2397-2404.
18. Kirchhoff AC, Leisenring W, Syrjala KL. Prospective predictors of return to work in the 5 years after hematopoietic cell trans- plantation. J Cancer Surviv. 2010;4(1):33-44.
19. Syrjala KL, Langer SL, Abrams JR, Storer BE, Martin PJ. Late effects of hematopoietic cell transplantation among 10-year adult sur- vivors compared with case-matched con- trols. J Clin Oncol. 2005;23(27):6596-6606.
20. Syrjala KL, Langer SL, Abrams JR, et al. Recovery and long-term function after hematopoietic cell transplantation for leukemia or lymphoma. JAMA. 2004;291(19):2335-2343.
21. Majhail NS, Brazauskas R, Rizzo JD, et al. Secondary solid cancers after allogeneic hematopoietic cell transplantation using busulfan-cyclophosphamide conditioning. Blood. 2011;117(1):316-322.
22. Majhail NS. Secondary cancers following allogeneic haematopoietic cell transplanta- tion in adults. Br J Haematol. 2011;154(3):301-310.
23. Sun CL, Kersey JH, Francisco L, et al. Burden of morbidity in 10+ year survivors of hematopoietic cell transplantation: report from the bone marrow transplantation sur- vivor study. Biol Blood Marrow Transplant. 2013;19(7):1073-1080.
24. Majhail NS, Rizzo JD, Lee SJ, et al. Recommended screening and preventive practices for long-term survivors after hematopoietic cell transplantation. Bone Marrow Transplant. 2012;47(3):337-341.
25. Majhail NS, Rizzo JD, Lee SJ, et al. Recommended screening and preventive practices for long-term survivors after hematopoietic cell transplantation. Biol Blood Marrow Transplant. 2012;18(3):348- 371.
26.
27.
28.
29.
30.
31.
32.
33.
34.
35.
36.
37.
38.
39.
40. 41.
Khera N, Chow EJ, Leisenring WM, et al. Factors associated with adherence to pre- ventive care practices among hematopoietic cell transplantation survivors. Biol Blood Marrow Transplant. 2011;17(7):995-1003. Bishop MM, Lee SJ, Beaumont JL, et al. The preventive health behaviors of long-term survivors of cancer and hematopoietic stem cell transplantation compared with matched controls. Biol Blood Marrow Transplant. 2010;16(2):207-214.
Armenian SH, Sun CL, Francisco L, et al. Health behaviors and cancer screening prac- tices in long-term survivors of hematopoiet- ic cell transplantation (HCT): a report from the BMT Survivor Study. Bone Marrow Transplant. 2012;47(2):283-290.
Hashmi SK, Bredeson C, Duarte RF, et al. National Institutes of Health Blood and Marrow Transplant Late Effects Initiative: The Healthcare Delivery Working Group Report. Biol Blood Marrow Transplant. 2017;23(5):717-725.
Majhail NS. Optimizing Quality and Efficiency of Healthcare Delivery in Hematopoietic Cell Transplantation. Curr Hematol Malig Rep. 2015;10(3):199-204. Khera N, Martin P, Edsall K, et al. Patient- centered care coordination in hematopoietic cell transplantation. Blood Adv. 2017; 1(19):1617-1627.
Mani S, Rybicki L, Carraway H, Moore H, Vakharia N, majhail NS. Primary care physi- cian preferences and perspectives on long- term care of survivors of hematologic malig- nancies and hematopoietic cell transplanta- tion. Biol Blood Marrow Transplant. 2016;22(3 (Suppl)):S85-86.
survivors and health care providers: a sys- tematic review and quality appraisal of the evidence. J Cancer Surviv. 2016; 10(1):71-86.
42. Brennan ME, Gormally JF, Butow P, Boyle FM, Spillane AJ. Survivorship care plans in cancer: a systematic review of care plan out- comes. Br J Cancer. 2014;111(10):1899-1908.
43. Denzen EM, Preussler JM, Murphy EA, et al. Tailoring a survivorship care plan: Patient and provider preferences for recipients of hematopoietic cell transplantation Biol Blood Marrow Transplant. 2018; S1083- 8791(18)30614-1.
44. Weiss BD, Mays MZ, Martz W, et al. Quick assessment of literacy in primary care: the newest vital sign. Ann Fam Med. 2005;3(6):514-522.
45. Palmer SC, Jacobs LA, Mao J, Stricker CT. Are cancer survivors confident in their knowledge about their disease and care? Poster presented at the 6th Biennial Cancer Survivorship Research: Translating Science to Care, June 14, 2012. Available from: https://smhs.gwu.edu/cancercontroltap/site s/cancercontroltap/files/CSI%20descrip- tion.pdf?src=TAPResource.
46. Syrjala KL, Chapko ME. Evidence for a biopsychosocial model of cancer treatment- related pain. Pain. 1995;61(1):69-79.
47. Ware J Jr, Kosinski M, Keller SD. A 12-Item Short-Form Health Survey: construction of scales and preliminary tests of reliability and validity. Med Care. 1996; 34(3):220-233.
48. Mayer DK, Nekhlyudov L, Snyder CF, Merrill JK, Wollins DS, Shulman LN. American Society of Clinical Oncology clin- ical expert statement on cancer survivorship care planning. J Oncol Pract. 2014;10(6):345-
Denzen EM, Majhail NS, Stickney Ferguson 351.
S, et al. Hematopoietic cell transplantation in 2020: summary of year 2 recommendations of the National Marrow Donor Program's System Capacity Initiative. Biol Blood Marrow Transplant. 2013;19(1):4-11. Majhail NS, Mau LW, Chitphakdithai P, et al. National Survey of Hematopoietic Cell Transplantation Center Personnel, Infrastructure, and Models of Care Delivery. Biol Blood Marrow Transplant. 2015;21(7):1308-1314.
Majhail NS, Murphy EA, Denzen EM, et al. The National Marrow Donor Program's Symposium on Hematopoietic Cell Transplantation in 2020: a health care resource and infrastructure assessment. Biol Blood Marrow Transplant. 2012; 18(2):172- 182.
McCabe MS, Bhatia S, Oeffinger KC, et al. American Society of Clinical Oncology statement: achieving high-quality cancer survivorship care. J Clin Oncol. 2013; 31(5):631-640.
Jacobsen PB, DeRosa AP, Henderson TO, et al. Systematic Review of the Impact of Cancer Survivorship Care Plans on Health Outcomes and Health Care Delivery. J Clin Oncol. 2018;36(20):2088-2100.
Salz T, Oeffinger KC, McCabe MS, Layne TM, Bach PB. Survivorship care plans in research and practice. CA Cancer J Clin. 2012;62(2):101-117.
Stricker CT, Jacobs LA, Risendal B, et al. Survivorship care planning after the institute of medicine recommendations: how are we faring? J Cancer Surviv. 2011; 5(4):358-370. Jacobs LA, Shulman LN. Follow-up care of cancer survivors: challenges and solutions. Lancet Oncol. 2017;18(1):e19-e29. Klemanski DL, Browning KK, Kue J. Survivorship care plan preferences of cancer
49. Blanch-Hartigan D, Forsythe LP, Alfano CM, et al. Provision and discussion of survivor- ship care plans among cancer survivors: results of a nationally representative survey of oncologists and primary care physicians. J Clin Oncol. 2014;32(15):1578-1585.
50. Hewitt ME, Bamundo A, Day R, Harvey C. Perspectives on post-treatment cancer care: qualitative research with survivors, nurses, and physicians. J Clin Oncol. 2007; 25(16):2270-2273.
51. Acquati C, Kayser K. Predictors of psycho- logical distress among cancer patients receiv- ing care at a safety-net institution: the role of younger age and psychosocial problems. Support Care Cancer. 2017; 25(7):2305- 2312.
52. Head BA, Schapmire TJ, Keeney CE, et al. Use of the Distress Thermometer to discern clinically relevant quality of life differences in women with breast cancer. Qual Life Res. 2012;21(2):215-223.
53. Jacobsen PB, Shibata D, Siegel EM, et al. Evaluating the quality of psychosocial care in outpatient medical oncology settings using performance indicators. Psychooncology. 2011;20(11):1221-1227.
54. Zebrack B, Kayser K, Sundstrom L, et al. Psychosocial distress screening implementa- tion in cancer care: an analysis of adherence, responsiveness, and acceptability. J Clin Oncol. 2015;33(10):1165-1170.
55. Syrjala KL, Sutton SK, Jim HS, et al. Cancer and treatment distress psychometric evalua- tion over time: A BMT CTN 0902 secondary analysis. Cancer. 2017;123(8):1416-1423.
56. Majhail NS, Nayyar S, Santibanez ME, Murphy EA, Denzen EM. Racial disparities in hematopoietic cell transplantation in the United States. Bone Marrow Transplant. 2012;47(11):1385-1390.